Healthcare / BiotechnologyHKSE
$3.11
+0.10 (+3.32%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-302.8M · quality 64.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
25/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.6B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-75.6%
↓Gross Margin
N/A
•Debt/Equity
0.41
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.72x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-232.1M · FCF $-167.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Net Income | $-232.1M | $-232.1M | $-381.8M | $-939.3M | $-190.2M |
| EBITDA | $-223.3M | $-223.3M | $-374.1M | $-937.0M | $-188.5M |
| EPS | -0.51 | -0.51 | -0.84 | -3.62 | -0.75 |
| Balance Sheet | |||||
| Debt/Equity | 0.41 | 0.41 | 0.18 | 0.02 | -0.02 |
| Current Ratio | 5.42 | 5.42 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-167.0M | $-167.0M | $-302.8M | $-357.4M | $-172.6M |
| Returns | |||||
| ROE | -75.6% | -75.6% | -90.0% | -133.7% | 40.4% |
| Valuation | |||||
| P/B | 4.86 | 4.86 | 1.18 | 4.46 | — |
| Growth & Yield | |||||
| EPS Growth | 39.3% | 39.3% | 76.8% | -382.7% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+18.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.84 → -0.51
Residual
+18.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.